Eisai

Dr. Richard Woodman Appointed Chief Clinical Officer of the Oncology Business Group at Eisai Inc.

Wednesday, January 20, 2021 - 12:55pm

WOODCLIFF LAKE, N.J., Jan. 20, 2021 /PRNewswire/ --Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Dr. Richard Woodman as Chief Clinical Officer (CCLO) of its Oncology Business Group.

Key Points: 
  • WOODCLIFF LAKE, N.J., Jan. 20, 2021 /PRNewswire/ --Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Dr. Richard Woodman as Chief Clinical Officer (CCLO) of its Oncology Business Group.
  • In this role, Dr. Woodman will have full oversight and responsibility for the strategic and operational leadership of the company's global oncology clinical development functions, including clinical research, clinical operations, imaging, medical writing, data services, biostatistics and regulatory strategy.
  • Before joining Eisai, Dr. Woodman served as Chief Medical Officer and Head of Research and Development at Onconova Therapeutics, where he was responsible for its late- and early-stage oncology development programs.
  • Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases).

Eisai Assembles World-Class Team, Led by SJP, to Manage Build-Out of New U.S. Headquarters

Tuesday, January 19, 2021 - 4:27pm

Continued and constant growth of the healthcare ecosystem is essential during these challenging times, said Joel Beetsch, PhD, Vice President of Corporate Affairs at Eisai Inc.

Key Points: 
  • Continued and constant growth of the healthcare ecosystem is essential during these challenging times, said Joel Beetsch, PhD, Vice President of Corporate Affairs at Eisai Inc.
  • The combination of healthcare innovation and the knowledge-creating space in which it takes place is a critical and powerful partnership.
  • Eisai deeply appreciates the expertise of SJP to help drive the delivery of healthcare solutions to patients and their families.
  • Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases).

Eisai to Present Abstracts on Lenvatinib at 2021 Gastrointestinal Cancers Symposium

Tuesday, January 12, 2021 - 3:37am

TOKYO, Jan 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, "lenvatinib") will be given at the Gastrointestinal Cancers Symposium Virtual Meeting, from January 15 to 17, 2021.

Key Points: 
  • TOKYO, Jan 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, "lenvatinib") will be given at the Gastrointestinal Cancers Symposium Virtual Meeting, from January 15 to 17, 2021.
  • In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.
  • Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer.
  • Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these Ricchi, with the aim of contributing to the cure of cancers.

Eisai Completes Construction of the 5th Manufacturing Building at Kawashima Industrial Park in Japan

Friday, December 18, 2020 - 4:09am

TOKYO, Dec 18, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced that it has completed construction of the 5th manufacturing building at the Kawashima Industrial Park located in Gifu Prefecture, Japan.

Key Points: 
  • TOKYO, Dec 18, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced that it has completed construction of the 5th manufacturing building at the Kawashima Industrial Park located in Gifu Prefecture, Japan.
  • The 5th manufacturing building is a facility specifically designated for formulating anti-cancer drugs (total floor area: approximately 4,500m2).
  • The total investment for the construction of the 5th manufacturing building is approximately 5 billion yen.
  • The Kawashima Industrial Park, opened in 1966, is Eisai?s global pharmaceutical manufacturing base.

Allarity Therapeutics Expands its Stenoparib License Rights to Include Anti-Viral Uses

Monday, December 14, 2020 - 12:45pm

Hrsholm, Denmark (14 December 2020) Allarity Therapeutics A/S (Allarity or the Company) today announced that it has amended its license agreement with Eisai Co., Ltd. (Tokyo, Japan) to expand Allaritys field-of-use to include anti-viral uses of Stenoparib (formerly E7449).

Key Points: 
  • Hrsholm, Denmark (14 December 2020) Allarity Therapeutics A/S (Allarity or the Company) today announced that it has amended its license agreement with Eisai Co., Ltd. (Tokyo, Japan) to expand Allaritys field-of-use to include anti-viral uses of Stenoparib (formerly E7449).
  • Allarity holds global, exclusive rights to the PARP inhibitor, Stenoparib, under an existing license with Eisai, in the field of cancer therapeutics and treatment.
  • With the amendment to the license, Allarity now further holds global, exclusive rights to the drug as an anti-viral therapy.
  • The expansion of the field-of-use rights will support Allarity in its advancement of Stenoparib as a potential anti-viral therapy for COVID-19.

Eisai: Biogen Files New Drug Application for Aducanumab in Japan

Friday, December 11, 2020 - 1:43am

- Aducanumab is now under regulatory review in Japan, Europe and the United States

Key Points: 
  • - Aducanumab is now under regulatory review in Japan, Europe and the United States
    TOKYO, Dec 11, 2020 - (JCN Newswire) - Biogen and Eisai, Co., Ltd. (Tokyo, Japan) announced that Biogen has submitted a Japanese New Drug Application (J-NDA) to the Ministry of Health, Labor and Welfare (MHLW) for aducanumab, an investigational therapy for Alzheimer's disease.
  • "Japan is the third market where we have applied for regulatory approval for aducanumab, and the filing represents continued progress on our commitment to bring this therapy to patients around the world," said Michel Vounatsos, Chief Executive Officer at Biogen.
  • "Japan has met the challenges of a rapidly-aging population by demonstrating global leadership in setting policies that aim to increase support for Alzheimer's disease patients and caregivers.
  • Aducanumab also has the potential to help address the public health challenges our aging population faces in Japan."

Biogen Files New Drug Application for Aducanumab in Japan

Thursday, December 10, 2020 - 3:30am

and TOKYO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Today, Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) announced that Biogen has submitted a Japanese New Drug Application (J-NDA) to the Ministry of Health, Labor and Welfare (MHLW) for aducanumab, an investigational therapy for Alzheimers disease.

Key Points: 
  • and TOKYO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Today, Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) announced that Biogen has submitted a Japanese New Drug Application (J-NDA) to the Ministry of Health, Labor and Welfare (MHLW) for aducanumab, an investigational therapy for Alzheimers disease.
  • Aducanumab also has the potential to help address the public health challenges our aging population faces in Japan.
  • If approved, aducanumab would be the first treatment to meaningfully change the course of the disease for individuals living with Alzheimers.
  • Since October 2017 Biogen and Eisai Co., Ltd. have collaborated on the development and commercialization of aducanumab globally.

Eisai Presents Long-Term Seizure Freedom And Real-World Data Related To Anti-Epileptic Drug FYCOMPA® At The AES 2020 Annual Meeting

Monday, December 7, 2020 - 3:15pm

WOODCLIFF LAKE, N.J., Dec. 7, 2020 /PRNewswire/ --Eisai Inc. presented 52-week seizure freedom data related to its antiepileptic drug (AED) FYCOMPA (perampanel) CIII at the 2020 American Epilepsy Society (AES) Annual Meeting virtual conference.

Key Points: 
  • WOODCLIFF LAKE, N.J., Dec. 7, 2020 /PRNewswire/ --Eisai Inc. presented 52-week seizure freedom data related to its antiepileptic drug (AED) FYCOMPA (perampanel) CIII at the 2020 American Epilepsy Society (AES) Annual Meeting virtual conference.
  • Effectiveness assessments comprised seizure freedom rate, responder rate, and the proportion of patients with unchanged or worsening seizure frequency.
  • The results are encouraging as we continue to work toward the goal of seizure freedom for patients taking antiepileptic drug therapy."
  • The seizure freedom rate was 62.5% in the mITT population (n=20/32) at 4 mg/day for 52 weeks.

Eisai to Present Abstracts on Oncology Products and Pipeline at 43rd Annual San Antonio Breast Cancer Symposium

Friday, December 4, 2020 - 3:17am

The results of analysis evaluating eribulin in the clinical practice in a subgroup of patients with metastatic breast cancer with a poor prognosis, in the United States, (Abstract No: PS13-37) will be published.

Key Points: 
  • The results of analysis evaluating eribulin in the clinical practice in a subgroup of patients with metastatic breast cancer with a poor prognosis, in the United States, (Abstract No: PS13-37) will be published.
  • In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.
  • Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer.
  • There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

Eisai to Present Latest Data on Perampanel at the 74th American Epilepsy Society Annual Meeting

Monday, November 30, 2020 - 5:04am

TOKYO, Nov 30, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will present the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa), at the 74th American Epilepsy Society Annual Meeting (AES2020), to be held virtually from December 4 to 8, 2020.

Key Points: 
  • TOKYO, Nov 30, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will present the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa), at the 74th American Epilepsy Society Annual Meeting (AES2020), to be held virtually from December 4 to 8, 2020.
  • As we provide perampanel globally, Eisai pursues its mission to provide "seizure freedom" to a greater number of patients with epilepsy.
  • Eisai seeks to address the diverse needs of, as well as increase the benefits provided to, patients with epilepsy and their families.
  • Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan.